| Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy E Sotillo, DM Barrett, KL Black, A Bagashev, D Oldridge, G Wu, ... Cancer discovery 5 (12), 1282-1295, 2015 | 1287 | 2015 |
| Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma MP Chao, AA Alizadeh, C Tang, JH Myklebust, B Varghese, S Gill, M Jan, ... Cell 142 (5), 699-713, 2010 | 1225 | 2010 |
| Human chimeric antigen receptor macrophages for cancer immunotherapy M Klichinsky, M Ruella, O Shestova, XM Lu, A Best, M Zeeman, ... Nature biotechnology 38 (8), 947-953, 2020 | 1141 | 2020 |
| Decade-long leukaemia remissions with persistence of CD4+ CAR T cells JJ Melenhorst, GM Chen, M Wang, DL Porter, C Chen, MKA Collins, ... Nature 602 (7897), 503-509, 2022 | 700 | 2022 |
| Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies M Ruella, DM Barrett, SS Kenderian, O Shestova, TJ Hofmann, ... The Journal of clinical investigation 126 (10), 3814-3826, 2016 | 631 | 2016 |
| Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell M Ruella, J Xu, DM Barrett, JA Fraietta, TJ Reich, DE Ambrose, ... Nature medicine 24 (10), 1499-1503, 2018 | 627 | 2018 |
| Macrophage-based approaches for cancer immunotherapy NR Anderson, NG Minutolo, S Gill, M Klichinsky Cancer research 81 (5), 1201-1208, 2021 | 543 | 2021 |
| Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells S Gill, SK Tasian, M Ruella, O Shestova, Y Li, DL Porter, M Carroll, ... Blood, The Journal of the American Society of Hematology 123 (15), 2343-2354, 2014 | 540 | 2014 |
| Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia JA Fraietta, KA Beckwith, PR Patel, M Ruella, Z Zheng, DM Barrett, ... Blood, The Journal of the American Society of Hematology 127 (9), 1117-1127, 2016 | 527 | 2016 |
| CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia SS Kenderian, M Ruella, O Shestova, M Klichinsky, V Aikawa, ... Leukemia 29 (8), 1637-1647, 2015 | 490 | 2015 |
| Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia MY Kim, KR Yu, SS Kenderian, M Ruella, S Chen, TH Shin, AA Aljanahi, ... Cell 173 (6), 1439-1453. e19, 2018 | 467 | 2018 |
| NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects JA Olson, DB Leveson-Gower, S Gill, J Baker, A Beilhack, RS Negrin Blood, The Journal of the American Society of Hematology 115 (21), 4293-4301, 2010 | 461 | 2010 |
| Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies S Gill, CH June Immunological reviews 263 (1), 68-89, 2015 | 444 | 2015 |
| Chimeric antigen receptor T cell therapy: 25 years in the making S Gill, MV Maus, DL Porter Blood reviews 30 (3), 157-167, 2016 | 297 | 2016 |
| Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells NR Mathew, F Baumgartner, L Braun, D O'Sullivan, S Thomas, ... Nature medicine 24 (3), 282-291, 2018 | 294 | 2018 |
| Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction N Singh, YG Lee, O Shestova, P Ravikumar, KE Hayer, SJ Hong, XM Lu, ... Cancer discovery 10 (4), 552-567, 2020 | 262 | 2020 |
| Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: a randomized clinical trial BS Abella, EL Jolkovsky, BT Biney, JE Uspal, MC Hyman, I Frank, ... JAMA internal medicine 181 (2), 195-202, 2021 | 238 | 2021 |
| Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia NV Frey, PA Shaw, EO Hexner, E Pequignot, S Gill, SM Luger, ... Journal of Clinical Oncology 38 (5), 415-422, 2020 | 235 | 2020 |
| Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells S Gill, AE Vasey, A De Souza, J Baker, AT Smith, HE Kohrt, M Florek, ... Blood, The Journal of the American Society of Hematology 119 (24), 5758-5768, 2012 | 218 | 2012 |
| The Addition of the BTK inhibitor Ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma M Ruella, SS Kenderian, O Shestova, JA Fraietta, S Qayyum, Q Zhang, ... Clinical Cancer Research 22 (11), 2684-2696, 2016 | 210 | 2016 |
